Related Experiment Video
Updated: Mar 31, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
PML: The Dark Side of Immunotherapy in Multiple Sclerosis
Clemens Warnke1, Tomas Olsson2, Hans-Peter Hartung1
1Department of Neurology, Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany.
Abstract:
Progressive multifocal leukoencephalopathy (PML) is a threat to patients with multiple sclerosis (MS) who undergo treatment with drugs that interfere with normal immune physiology. Here, we summarize PML incidence in MS, risk factors, surveillance strategies, and case definitions to inform neurologists and other clinicians treating patients with immune-mediated diseases.
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

